The ProSense® Cryoablation System:

A new hope in breast care

ProSense® is a liquid nitrogen (LN2) based cryoablation system with a powerful, compact, and user-friendly design for maximum efficacy in breast tumor destruction. 

promising ICE3 interim results

Based on interim analysis performed in July 2022



Eligible Patients for Cryoablation



(Including Columbia University Medical Center and Mount Sinai Beth Israel)


Patients Followed For 5 Years*

*As of July 2022



Recurrence Free as of July 2022

188 out of the 194 eligible patients did not have recurrence



Safe Procedure

No significant device-related adverse events or complications have been reported


Doctor Satisfaction
with Cosmetic Results


Patient Satisfaction
with Cosmetic Results

No scarring or change to the shape and size of the breast


Clinically proven

Clinically proven

Cost effective in-office treatment

Short treatment time for fibroadenomas –
only 5-15 minutes

Touche Screen

Touch-screen console

ProSense Cryoablation System by IceCure Medical
Choice of probes

Choice of probes for
customized treatment

(small disposable

Low pressure, safe, convenient and easy to use

Low pressure, safe,
convenient and easy to

Painless with immediate return to daily activities

Painless with immediate return to daily activities

FDA 510(k) cleared and CE marked

FDA cleared
and CE marked


The ProSense™ system is considered an optimal solution for treating breast tumors.


ProSense is FDA-cleared and has successfully been treating fibroadenomas since clinical trials began in 2012.


“The FDA has approved the use of cryoablation as a safe and effective therapy for fibroadenomas.” 

American Society of Breast Surgeon’s (ASBrS) Consensus Statement for Management of Fibroadenomas of the Breast

ICE3 Trial 

ICE3 is the largest controlled multilocation clinical trial ever performed for nitrogen-based cryoablation of small, low-risk, early stage malignant breast tumors without subsequently removing them.


of trial participants did not have recurrence as of April 2021. 

Interim results presented at the 2021 Annual ASBrS Meeting by Dr. Richard E. Fine, MD  

 “Cryoablation offers an exciting, minimally invasive option to open surgery in the treatment of small, early-stage breast cancer tumors. The innovative Liquid Nitrogen (LN2) based ProSense® System provides more efficient, targeted treatment to completely destroy the tumor in a quick, office-based procedure”

Professor Eisuke Fukuma, MD, PhD, Chairman of Breast Center, Kameda Medical Center, Japan 

Watch the ICE3 Study Update at ASBrS 2021

This 2021 ASBrS exhibitor learning session was moderated by ICE3 investigator Dr. Richard E. Fine who discussed the ICE3 Clinical Trial on Cryoablation in Small, Low-Risk Breast Cancer Interim Results. 

Case studies were provided by fellow ICE3 Investigators Dr. Susan A. Seedman and Dr. Michael Berry.

In this webinar you will learn about:

  • Overview of the ProSense® Liquid Nitrogen Cryoablation System
  • ICE3 Interim Results on the Cryoablation of Small Low-Risk, Breast Cancer as presented at ASBrS 2021
  • Two ICE3 trial case studies
  • Question and Answer Session